News Release

Contacts:

Integra LifeSciences Holdings Corporation

John B. Henneman, III                      Maria Platsis
Executive Vice President                   Vice President, Corporate Development
Chief Administrative Officer               (609) 936-2333
(609) 936-2481                             mplatsis@Integra-LS.com
jhenneman@Integra-LS.com


                 Integra LifeSciences Closes its Acquisition of
                             Kinetikos Medical, Inc.

Plainsboro, New Jersey / August 2, 2006 -- Integra LifeSciences Holdings
Corporation (NASDAQ: IART) announced today that it has acquired the shares of
Kinetikos Medical, Inc. ("KMI") for approximately $40 million in cash, subject
to certain adjustments, including future payments based on the performance of
the KMI business after the acquisition.

KMI, based in Carlsbad California, is a leading developer and manufacturer of
innovative orthopedic implants and surgical devices for small bone and joint
procedures involving the foot, ankle, hand, wrist and elbow. KMI generated
revenues of $11.4 million for the twelve months ended March 31, 2006.

"We are excited to add KMI's people and products to the Integra reconstructive
surgery team," said Stuart M. Essig, Integra's President and Chief Executive
Officer. "KMI is an ideal strategic fit with our growing extremity business and
strengthens our presence in the orthopedic hand market. This acquisition allows
us to leverage our current and future regenerative products for dermal, tendon
and nerve repair targeted for hand surgery. We expect to benefit from the
synergy between KMI's upper extremity orthopedic implant products and these
regenerative products, including the INTEGRA(R) Dermal Regeneration Template,
the INTEGRA(R) Bilayer and single-layer Matrix Wound Dressings, NeuraGen(TM) and
NeuraWrap(TM). In addition, KMI's product range in the foot and ankle market
holds strong brand identity and complements our rapidly growing Newdeal
business."

KMI has an experienced senior management team with a proven track record in the
orthopedics device industry, which has now joined Integra.

KMI currently markets products that address both the trauma and reconstructive
segments of the extremities market. KMI's reconstructive products are largely
focused on treating deformities and arthritis in small joints of the upper and
lower extremity, while its trauma products are focused on the treatment of
fractures of small bones most commonly found in the extremities.

KMI's products include the UNI2, which is recognized as the premier implant for
wrist replacement, a procedure that restores the function of the arthritic
wrist. The Subtalar Maxwell-Brancheau Arthroereisis System ("MBA"), another of
KMI's products, is the market leading product that provides a simple and
effective means of correcting debilitating flatfoot for both pediatric and adult
patients. KMI currently sells its products through approximately 45 independent
sales agencies in the United States and through 17 independent distributors
internationally. Approximately 89% of KMI's sales are generated in the United
States. Integra looks forward to expanding the sale of KMI products
internationally through its well-established Newdeal infrastructure.




"We are very excited to join the Integra LifeSciences family of companies," said
Jim Ham, General Manager of KMI. "We look forward to expanding our business
within Integra. In particular, we believe the combination of Integra's portfolio
of collagen tissue-engineered products and KMI's upper extremity orthopedic
implants creates an opportunity for revenue synergy. We and the management of
Integra will work together to integrate KMI into Integra so that the combined
business can maximize these revenue synergies. Together we can offer a broad
package of solutions for the orthopedic hand, foot and ankle, reconstructive and
podiatric surgeons."

First Albany Capital served as advisor to KMI for the transaction.

Integra LifeSciences Holdings Corporation is a diversified medical technology
company that develops, manufactures, and markets medical devices for use in a
variety of applications. The primary applications for our products are
neurosurgery, reconstructive surgery and general surgery. Integra is a leader in
applying the principles of biotechnology to medical devices that improve
patients' quality of life. Our corporate headquarters are in Plainsboro, New
Jersey, and we have manufacturing and research facilities located throughout the
world. We have approximately 1,650 employees. Please visit our website at
(http://www.Integra-LS.com).

This news release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
include, but are not limited to, statements concerning expectations for this
newly acquired business and the expected impact of this acquisition on Integra's
future financial results. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially from
predicted or expected results. Among other things, Integra's ability to
successfully integrate KMI into its operations could affect the impact of this
acquisition on Integra's future financial results. In addition, the economic,
competitive, governmental, technological and other factors identified under the
heading "Factors That May Affect Our Future Performance" included in the
Business section of Integra's Annual Report on Form 10-K for the year ended
December 31, 2005 and information contained in subsequent filings with the
Securities and Exchange Commission could affect actual results.

Source: Integra LifeSciences Holdings Corporation